Proassurance CORP

ProAssurance Corporation has finalized its merger with The Doctors Company, resulting in its transition to a wholly owned subsidiary and subsequent delisting from the NYSE.

ProAssurance Corporation provides an update on its pending merger with The Doctors Company, confirming significant regulatory approvals and reiterating an anticipated closing date.

ProAssurance Corporation announced first quarter 2026 results, reporting net income of $8.5 million and operating income of $12.7 million, while continuing to navigate regulatory approvals for its merger with The Doctors Company.

ProAssurance Corporation announced significant increases in operating income and improved combined ratios for Q4 and full-year 2025, alongside continued progress on its merger with The Doctors Company.

ProAssurance Corporation's Compensation Committee approved cash incentive awards for named executive officers to mitigate potential Section 280G impacts ahead of its merger with The Doctors Company.

ProAssurance reported a significant drop in Q3 net income but saw improved nine-month operating income and advanced its merger with The Doctors Company.

ProAssurance Corporation reported a net income of $8.46 million for Q1 2026, a significant improvement from a net loss in the prior year, despite a 5.4% decrease in net premiums earned.

ProAssurance Corporation reported a significant decline in net income and earnings per share for the third quarter and first nine months of 2025, primarily due to increased transaction-related costs for its pending merger with The Doctors Company and higher loss ratios.

ProAssurance Corporation reported a decrease in net income for the second quarter and first half of 2025, driven by merger-related costs and investment losses, despite favorable loss reserve development and improved underwriting ratios.

ProAssurance Corporation's Q1 2025 results reveal a net loss, impacted by transaction-related costs and foreign exchange losses, while the company progresses with its merger agreement with The Doctors Company.

ProAssurance Corporation's Q3 2024 results show a complex picture with improved underwriting in some areas offset by challenges in others, alongside strategic adjustments in its investment portfolio.

ProAssurance Corporation's second quarter results show a mixed performance with a decrease in net premiums earned but an increase in net investment income.

ProAssurance Corporation files an amendment to its 2025 10-K report to include previously omitted Part III information, including details on directors, executive compensation, and corporate governance.

ProAssurance Corporation reported improved operating and combined ratios for 2025, driven by significant favorable reserve development, as it progresses towards a cash acquisition by The Doctors Company.

ProAssurance Corporation reports a net income of $52.7 million for the year ended December 31, 2024, a significant turnaround from the $38.6 million net loss in the previous year, driven by improvements in underwriting and investment performance.

ProAssurance Corporation's 2023 annual report reveals a year of strategic adjustments, including a segment reorganization and the discontinuation of participation in a Lloyd's syndicate, alongside challenges in the competitive insurance market.

ProAssurance Corporation's merger with The Doctors Company has been finalized, with common stock and deferred shares converted into a cash payout of $25 per share.

ProAssurance Corporation's merger with The Doctors Company subsidiary has been finalized, resulting in the conversion of director deferred stock into cash payments.

ProAssurance Corporation's merger with The Doctors Company subsidiary, Jackson Acquisition Corporation, has been finalized, resulting in Bruce D. Angiolillo's beneficial ownership of common stock being converted to cash.

ProAssurance Corporation's merger with The Doctors Company has been finalized, with Director Katisha T. Vance reporting transactions related to her holdings.

ProAssurance Corporation's merger with The Doctors Company subsidiary, Jackson Acquisition Corporation, has been finalized, converting outstanding common stock and deferred shares into cash payments.

ProAssurance Corporation's merger with The Doctors Company has been finalized, resulting in executive Dana S. Hendricks' beneficial ownership of common stock being converted to cash.

ProAssurance stockholders will receive $25 per share in cash as The Doctors Company acquires the company in a merger transaction.

ProAssurance details progress on its acquisition by The Doctors Company, including upcoming stockholder meetings and regulatory filings.

ProAssurance has agreed to be acquired by The Doctors Company, creating the second-largest medical malpractice insurance company in the US.

ProAssurance Corporation issues a supplement to its proxy statement to correct an error regarding the treatment of abstentions for two proposals at the upcoming Annual Meeting of Stockholders.

ProAssurance releases an updated FAQ for employees regarding the proposed acquisition by The Doctors Company, addressing questions about the transaction's impact on employment, benefits, and operations.

ProAssurance Corporation has filed a definitive proxy statement with the Securities and Exchange Commission.

Magnetar Financial and its affiliates have filed an exit amendment to their Schedule 13D, confirming they no longer hold beneficial ownership of ProAssurance Corporation shares following the company's merger.

Magnetar Financial and its affiliates have disclosed a 5.9% beneficial ownership stake in ProAssurance Corp, acquired primarily for merger arbitrage purposes following the announcement of its acquisition by The Doctors Company for $25.00 per share.

Vanguard Capital Management has reported beneficial ownership of 5.09% of ProAssurance Corp's common stock as of March 31, 2026.

Vanguard Portfolio Management has reported beneficial ownership of 2,800,643 shares, representing 5.44% of ProAssurance Corp's common stock as of March 31, 2026.

Dimensional Fund Advisors LP has disclosed a beneficial ownership of 1,442,782 shares, representing 2.8% of the outstanding common stock of ProAssurance Corp as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting zero beneficial ownership in ProAssurance Corp following an internal realignment.

AllianceBernstein L.P. has reported a 5.3% beneficial ownership stake in ProAssurance Corp. common stock, held for investment purposes.

Wellington Management Group LLP and its affiliates have filed an amended Schedule 13G, reporting a beneficial ownership of 1.54% in ProAssurance Corporation's common stock as of March 31, 2025.